Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side ...

It's a very busy and spooky Halloween eve today — several companies had big misses in earnings reported this morning. Let's ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...